Proposal for Roflumilast

Below is a comprehensive evaluation of roflumilast as a repurposing candidate for Inclusion Body Myositis (IBM). The discussion is organized into the following sections: Overview of Therapeutic Candidate, Therapeutic History, Mechanism of Action, Expected Effect, and Overall Evaluation. Each section draws on information from the available context.

Overview of Therapeutic Candidate
Roflumilast is a fully synthetic small-molecule compound that emerged from extensive medicinal chemistry efforts designed to develop selective inhibitors of phosphodiesterase-4 (PDE4). The development strategy focused on systematically modifying a benzamide scaffold to improve selectivity for PDE4 isoenzymes while reducing binding to the high-affinity rolipram binding site (HARBS), an approach that ultimately improved tolerability over earlier compounds such as rolipram. This process—and the associated chemical optimizations—led to roflumilast’s well-characterized chemical profile as a PDE4 inhibitor. By targeting PDE4 enzymes, roflumilast works to prevent the degradation of cyclic adenosine monophosphate (cAMP), thereby causing an elevation in intracellular cAMP concentrations. This increase sets off a cascade of downstream reactions that include the activation of protein kinase A (PKA) and transcription factors like cyclic AMP response element-binding protein (CREB), which then modulate immune and inflammatory responses. Over the years, compounds in the PDE4 inhibitor class have been predominantly used for treating chronic inflammatory airway diseases—most notably chronic obstructive pulmonary disease (COPD) and asthma—by reducing inflammatory cytokine production and improving lung function (Crocetti et al., 2022, pp. 2–4; Page, 2015, pp. 5–6). This strong pharmacological background and well‐defined chemical origin provide a solid foundation for repurposing roflumilast for disorders where inflammation and defective protein clearance, such as IBM, play central roles.

Therapeutic History
Historically, roflumilast has achieved regulatory approval in both Europe and the United States for the maintenance therapy of severe COPD, particularly in patients who experience chronic bronchitis and frequent exacerbations. Although its primary clinical use has been within pulmonary medicine, the biochemical effects of PDE4 inhibition have been demonstrated in various preclinical studies to extend beyond the lungs. For instance, investigations in animal models and cultured human myotubes have revealed that PDE4 inhibitors such as roflumilast can modulate muscle protein turnover. In one study investigating muscle cells derived from patients with COPD cachexia, roflumilast treatment led to significant reductions in markers of proteolysis—specifically through decreased protein ubiquitination and reduced tyrosine release—as well as upregulation of contractile proteins such as myosin heavy chain isoforms (Barreiro et al., 2018, pp. 13–14; Lira et al., 2011, pp. 6–8). Despite these promising findings in muscle-wasting models, no clinical trials have yet been registered that specifically examine roflumilast in the context of IBM or other primary muscle diseases. Searches using terms such as “Roflumilast AND myositis” or “PDE4 inhibitors AND muscle” confirm that the agent’s application in primary inflammatory myopathies remains untested (ClinicalTrials.gov, n.d.). Collectively, the historical data indicate that although roflumilast has a proven record in treating COPD through its systemic anti-inflammatory actions, its use in IBM remains a novel and uncharted area that is supported largely by preclinical evidence from related muscle-wasting conditions.

Mechanism of Action
At the molecular level, the primary mode of action of roflumilast is the selective inhibition of the PDE4 family of enzymes, including isoforms PDE4A, PDE4B, and PDE4D, which are expressed in both immune and structural cells. PDE4 plays an essential role in hydrolyzing cAMP, a second messenger that regulates inflammation, immune cell activation, and intracellular protein degradation pathways. Inhibition of PDE4 by roflumilast leads to sustained elevations in intracellular cAMP levels. This increase activates PKA, which in turn phosphorylates downstream effectors such as CREB. These transcription factors alter gene expression and mediate anti-inflammatory effects—for instance, by reducing the synthesis and release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) and interleukin-1β (IL-1β) (Al-Sajee et al., 2019, pp. 3–4). Equally important is the role of cAMP signaling in promoting autophagy, a cellular clearance mechanism critical for eliminating aggregates of misfolded proteins. In skeletal muscle cells, the PKA-dependent phosphorylation of ULK1 has been shown to initiate autophagic processes that help clear toxic protein aggregates, a pathological hallmark observed in IBM (Barreiro et al., 2018, p. 2; Aringer et al., 2024, pp. 3–4). In addition to autophagy, elevated cAMP may enhance mitochondrial biogenesis and upregulate antioxidant defenses through the activation of essential transcription factors, thereby contributing to improved cellular energy metabolism and reducing oxidative stress—a further benefit for muscle contractile function (Herrmann et al., 2022, pp. 3–4; Nio et al., 2017, pp. 6–10). Furthermore, preclinical models have demonstrated that treatment with PDE4 inhibitors reduces the expression of atrogenes (such as atrogin-1 and MuRF-1) and decreases overall muscle proteolysis, thereby preserving the integrity of contractile proteins within skeletal muscle fibers (Lira et al., 2011, pp. 6–8). Thus, the molecular cascade initiated by roflumilast—in which PDE4 inhibition leads to increased cAMP, heightened PKA activity, suppression of NF-κB–mediated cytokine production, and enhanced autophagy—provides a comprehensive mechanistic rationale for its potential therapeutic benefits in inflammatory muscle disorders like IBM (Al-Sajee et al., 2019, pp. 7–8; Spina, 2008, p. 8).

Expected Effect
Based on its molecular pharmacological profile, roflumilast is expected to have several beneficial effects when applied to IBM myotubes. First, the inhibition of PDE4 will result in the accumulation of intracellular cAMP in skeletal muscle cells. The subsequent rise in cAMP levels is anticipated to augment PKA activity, leading to the phosphorylation of downstream substrates such as CREB and ULK1. The phosphorylation of ULK1 is particularly critical, as it initiates autophagosome formation and facilitates the clearance of aggregated proteins. In IBM, where protein aggregation and impaired autophagy are central pathological features, such an effect would likely help in restoring proteostasis (Barreiro et al., 2018, p. 2; Aringer et al., 2024, pp. 7–8).

Second, the increased cAMP/PKA signaling cascade is expected to downregulate the activity of the nuclear factor kappa B (NF-κB) pathway, thereby reducing the production of pro-inflammatory cytokines such as TNFα and IL-1β. These cytokines are known to exacerbate inflammatory damage and promote muscle degeneration in IBM. By mitigating the release of these mediators, roflumilast could help to alleviate the chronic inflammation that characterizes the disease (Al-Sajee et al., 2019, pp. 7–8; Contreras et al., 2017, pp. 1–2).

Third, the anti-inflammatory and autophagy-inducing effects of roflumilast are also anticipated to impact muscle proteostasis positively. In studies involving COPD cachexia, treatment with roflumilast has been correlated with a reduction in proteolytic markers such as protein ubiquitination and tyrosine release, accompanied by an upregulation of contractile proteins such as myosin heavy chain isoforms (Barreiro et al., 2018, pp. 13–14; Lira et al., 2011, pp. 6–8). These effects would theoretically translate into improved muscle fiber integrity and enhanced contractile performance in IBM myotubes. Additionally, there is preclinical evidence that PDE4 inhibitors can promote mitochondrial biogenesis and reduce oxidative stress, factors that would further support muscle function and potentially mitigate the muscle weakness often seen in IBM (Herrmann et al., 2022, pp. 3–4; Nio et al., 2017, pp. 6–10).

Finally, the overall combined effect of reduced proteolysis, improved autophagic clearance, and dampened inflammatory signaling is expected to create a more favorable cellular environment for muscle regeneration and maintenance. In vitro studies of muscle cells have demonstrated that improvements in these cellular processes correlate with better muscle contractility and enhanced cell survival. Expression analyses in cultured myotubes have confirmed the presence of key components of the cAMP/PKA signaling pathway and autophagy regulators, supporting the hypothesis that roflumilast will act effectively in the IBM cellular milieu (Al-Sajee et al., 2019, pp. 4–5; Nio et al., 2017, pp. 4–6).

Overall Evaluation
The repurposing of roflumilast for the treatment of Inclusion Body Myositis is supported by a robust mechanistic rationale and encouraging preclinical evidence from related models of muscle wasting and inflammation. One of the principal strengths of roflumilast lies in its well-established clinical safety profile in COPD, where its oral bioavailability and predictable pharmacokinetics have been validated in large randomized clinical trials (Garnock-Jones, 2015, pp. 1–2; de Mey et al., 2011, p. 13). This extensive clinical experience offers a significant regulatory and translational advantage if preliminary efficacy data in muscular models prove to be favorable.

On a mechanistic level, roflumilast’s selective inhibition of PDE4 results in a multi-pronged therapeutic approach that aligns well with the pathogenesis of IBM. By elevating intracellular cAMP levels, roflumilast not only suppresses the NF-κB–mediated production of pro-inflammatory cytokines but also activates PKA-dependent pathways that promote autophagy through ULK1 phosphorylation. These molecular effects are particularly relevant given that IBM is characterized by chronic inflammation, protein aggregation, and impaired autophagic clearance—all of which contribute to progressive muscle degeneration (Al-Sajee et al., 2019, pp. 7–8; Crocetti et al., 2022, pp. 21–22; Spina, 2008, p. 8). Preclinical data in muscle-wasting conditions further reinforce the notion that PDE4 inhibition can reduce proteolytic markers and enhance the expression of contractile proteins, suggesting that the therapy might translate into improved muscle mass and contractile strength (Barreiro et al., 2018, pp. 13–14; Lira et al., 2011, pp. 6–8).

However, several challenges must be considered. Perhaps the most critical limitation is the lack of direct clinical or preclinical evidence demonstrating roflumilast’s efficacy in IBM. Clinical trial registries show no studies that have directly evaluated PDE4 inhibition in IBM patients (ClinicalTrials.gov, n.d.). Thus, while the mechanistic rationale is compelling, substantial proof-of-concept studies in relevant in vitro and animal models of IBM are needed before translation into the clinic can be seriously considered.

Another potential concern is related to the side-effect profile of PDE4 inhibitors. Although roflumilast is generally well tolerated in COPD populations, its most common adverse events include gastrointestinal disturbances (such as nausea and diarrhea) and weight loss. These side effects could be particularly problematic in an older IBM patient population, which may exhibit heightened sensitivity to such adverse effects (Garnock-Jones, 2015, pp. 11–12; Spina, 2008, p. 8). Additionally, given the complexity of IBM, which involves not only inflammatory processes but also specific patterns of immune cell infiltration, protein aggregation, and mitochondrial dysfunction, it is plausible that PDE4 inhibition might need to be combined with other therapeutic strategies to achieve a meaningful clinical benefit (Crocetti et al., 2022, pp. 21–22; Aringer et al., 2024, pp. 7–8).

Despite these challenges, the overall benefits of roflumilast’s pharmacological profile—namely, its capacity to modulate chronic inflammation, enhance autophagic clearance, and preserve muscle proteostasis—make it a very attractive candidate for repurposing in IBM. The fact that its mechanism of action targets multiple pathogenic pathways suggests potential advantages over therapies that focus on a single aspect of muscle degeneration.

Future research should prioritize rigorous preclinical studies in cellular models that recapitulate the pathological features of IBM. In particular, experiments in cultured IBM myotubes should assess whether roflumilast can indeed elevate cAMP levels sufficiently to activate PKA and induce ULK1-dependent autophagy, as well as whether this translates into a measurable reduction in inflammatory cytokine production (e.g., TNFα and IL-1β) and proteolytic markers. Complementary in vivo studies in animal models of inflammatory myopathy would be essential to evaluate improvements in muscle contractility and overall function. These studies should also address potential adverse effects, with careful attention paid to dosing regimens that balance efficacy with tolerability.

In summary, roflumilast presents as a promising candidate for repurposing in Inclusion Body Myositis based on the following key strengths:

1. Its chemical and pharmacological profile as a selective PDE4 inhibitor is well established, with a clear mechanism that increases intracellular cAMP and subsequently activates PKA. This mechanistic cascade leads to downstream suppression of NF-κB–mediated inflammatory cytokine production and induction of autophagy, both of which are highly relevant to IBM pathology (Al-Sajee et al., 2019, pp. 3–4; Spina, 2008, p. 8).
2. Preclinical studies in muscle-wasting conditions, such as those involving COPD cachexia, have shown that roflumilast can reduce proteolytic markers and upregulate contractile proteins, supporting the hypothesis that its use could preserve muscle mass and improve function in IBM (Barreiro et al., 2018, pp. 13–14; Lira et al., 2011, pp. 6–8).
3. Its long-term clinical use and approval in COPD provide a favorable translational pathway. The established oral dosing and known systemic safety profile are advantageous when considering a repurposing strategy (Garnock-Jones, 2015, pp. 1–2; de Mey et al., 2011, p. 13).

On the other hand, the weaknesses include:

1. The complete absence of direct preclinical or clinical evidence specific to IBM. The critical extrapolation from COPD-related muscle wasting to IBM remains to be empirically validated (ClinicalTrials.gov, n.d.).
2. The potential for adverse effects such as gastrointestinal disturbances and weight loss, which may be particularly problematic in the elderly IBM patient population (Garnock-Jones, 2015, pp. 11–12; Spina, 2008, p. 8).
3. The multifactorial nature of IBM, where defective autophagy, chronic inflammation, protein aggregation, and mitochondrial dysfunction all converge, suggests that even if roflumilast addresses some of these pathways, it may require combination with other therapeutic interventions to achieve robust clinical improvement (Crocetti et al., 2022, pp. 21–22; Aringer et al., 2024, pp. 7–8).

Overall, while significant further investigation is warranted, the integrated biochemical, molecular, and preclinical evidence strongly supports the idea that roflumilast could offer therapeutic benefits in IBM. Its ability to elevate cAMP, drive PKA-dependent autophagy induction, suppress pro-inflammatory cytokine production, and favorably modulate muscle proteostasis directly addresses several key aspects of IBM pathobiology. Therefore, roflumilast merits further evaluation in targeted preclinical studies using IBM models, followed by carefully designed early-phase clinical trials if the preliminary results are encouraging (Al-Sajee et al., 2019, pp. 7–8; Crocetti et al., 2022, pp. 21–22; Aringer et al., 2024, pp. 3–4).

In conclusion, roflumilast offers a multifaceted therapeutic approach that, if validated, could significantly impact the progression of Inclusion Body Myositis. The potential to simultaneously modulate autophagy, suppress inflammatory cytokine release, and improve muscle contractile properties is highly compelling. Given the current unmet medical need in IBM and the relative safety of roflumilast as established in COPD populations, pursuing rigorous preclinical investigations and eventual clinical trials is a justified and promising direction for drug development.

References
Al-Sajee, D., Yin, X., & Gauvreau, G. M. (2019). An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma. Expert Opinion on Pharmacotherapy, 20(6), 609–620. https://doi.org/10.1080/14656566.2019.1570132

Aringer, M., Distler, O., Hoffmann-Vold, A.-M., Kuwana, M., Prosch, H., & Volkmann, E. R. (2024). Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open, 10(1), e004704. https://doi.org/10.1136/rmdopen-2024-004704

Barreiro, E., Puig-Vilanova, E., Salazar-Degracia, A., Pascual-Guardia, S., Casadevall, C., & Gea, J. (2018). The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia. Journal of Applied Physiology, 125(1), 287–303. https://doi.org/10.1152/japplphysiol.00798.2017

Contreras, S., Milara, J., Morcillo, E., & Cortijo, J. (2017). Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: Current and future evidences. Current Pharmaceutical Design. https://doi.org/10.2174/1381612823666170214105651

Crocetti, L., Floresta, G., Cilibrizzi, A., & Giovannoni, M. P. (2022). An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules, 27(15), 4964. https://doi.org/10.3390/molecules27154964

de Mey, C., Nassr, N., & Lahu, G. (2011). No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: An open-label, randomised, actively controlled study. BMC Clinical Pharmacology, 11, 7. https://doi.org/10.1186/1472-6904-11-7

Garnock-Jones, K. P. (2015). Roflumilast: A review in COPD. Drugs, 75(14), 1645–1656. https://doi.org/10.1007/s40265-015-0463-1

Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022). BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 13, 838449. https://doi.org/10.3389/fphar.2022.838449

Lira, E. C., Gonçalves, D. A. P., Parreiras-E-Silva, L. T., Zanon, N. M., Kettelhut, I. C., & Navegantes, L. C. C. (2011). Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle & Nerve. https://doi.org/10.1002/mus.22066

Nio, Y., Tanaka, M., Hirozane, Y., Muraki, Y., Okawara, M., Hazama, M., & Matsuo, T. (2017). Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy. The FASEB Journal, 31(12), 5307–5320. https://doi.org/10.1096/fj.201700249R

Page, C. P. (2015). Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. International Archives of Allergy and Immunology, 165(3), 152–164. https://doi.org/10.1159/000368800

Spina, D. (2008). PDE4 inhibitors: Current status. British Journal of Pharmacology, 155(3), 308–315. https://doi.org/10.1038/bjp.2008.307
